Zapaq Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Zapaq General Information

Description

Operator of a bio pharmaceutical company. The company focuses research on the development of drugs that inhibit a key enzyme involved in the production of beta-amyloid.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1050 Winter Street
  • Suite 1000
  • Waltham, MA 02451
  • United States
+1 (781)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1050 Winter Street
  • Suite 1000
  • Waltham, MA 02451
  • United States
+1 (781)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zapaq Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 14-Aug-2006 Completed Clinical Trials - General
3. Early Stage VC (Series B) 20-Sep-2005 Completed Startup
2. Early Stage VC (Series A2) 18-Mar-2004 $6.02M $11.2M Completed Startup
1. Early Stage VC (Series A1) 01-Mar-2004 $5.16M $5.16M Completed Startup
To view Zapaq’s complete valuation and funding history, request access »

Zapaq Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A2
Series A1 570,561 $0.001000 8% $2 $2 $2 1.47%
To view Zapaq’s complete cap table history, request access »

Zapaq Patents

Zapaq Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20070117793-A1 E.g. n1-(4-(3-(fluoromethyl)benzylamino)-3-hydroxy-1-phenylbutan-2-yl)-n3-methyl-n3-((4-methylthiazol-2-yl)methyl)isophthalamide;2 beta-secretase inhibitor; decrease hydrolysis of a beta -secretase site of a memapsin 2 substrate; alzheimer's disease Active 08-Apr-2005
US-20050239684-A1 Selectively inhibit memapsin 2 beta -secretase activity relative to memapsin 1 beta -secretase activity; alzheimer's disease Active 23-Oct-2001
US-20060234944-A1 Selectively inhibit memapsin 2 beta -secretase activity relative to memapsin 1 beta -secretase activity; alzheimer's disease Inactive 23-Oct-2001 C07K7/06

Zapaq Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Astellas Venture Management Corporate Venture Capital Minority
Oklahoma Life Science Fund Venture Capital Minority
Sanderling Ventures Venture Capital Minority
The Estée Lauder Companies Corporation Minority
To view Zapaq’s complete investors history, request access »

Zapaq FAQs

  • When was Zapaq founded?

    Zapaq was founded in 2000.

  • Where is Zapaq headquartered?

    Zapaq is headquartered in Waltham, MA.

  • What industry is Zapaq in?

    Zapaq’s primary industry is Drug Discovery.

  • Is Zapaq a private or public company?

    Zapaq is a Private company.

  • What is Zapaq’s current revenue?

    The current revenue for Zapaq is .

  • How much funding has Zapaq raised over time?

    Zapaq has raised $17.9M.

  • Who are Zapaq’s investors?

    Astellas Venture Management, Oklahoma Life Science Fund, Sanderling Ventures, and The Estée Lauder Companies have invested in Zapaq.

  • When was Zapaq acquired?

    Zapaq was acquired on 14-Aug-2006.

  • Who acquired Zapaq?

    Zapaq was acquired by CoMentis (Drug Discovery).

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process